Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

PHASE2TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

September 10, 2020

Study Completion Date

May 3, 2021

Conditions
Granulomatosis With Polyangiitis (GPA)Microscopic Polyangiitis (MPA)
Interventions
DRUG

IFX-1 low dose

Single IV infusions of IFX-1

DRUG

IFX-1 high dose

Single IV infusions of IFX-1

DRUG

Placebo

Placebo

Trial Locations (38)

10021

Hospital for Special Surgery, New York

11042

Northwell Health, LLC PRIME, New Hyde Park

14642

University of Rochester Medical Center - Strong Memorial Hospital, Rochester

16635

Altoona Center for Clinical Research, P.C., Duncansville

17011

BRCR Medical Center, Inc., Camp Hill

19104

University of Pennsylvania, Philadelphia

21224

Johns Hopkins Bayview Medical Center, Baltimore

22903

UVA University Physicians Charlottesville, Charlottesville

26506

West Virginia University, Morgantown

29406

Low Country Rheumatology, PA, North Charleston

33136

University of Miami, Miami

33166

Science Connections, LLC, Doral

43203

Ohio State University Clinical Trials Management Office, Columbus

48084

Henry Ford Hospital, Detroit

48109

University Of MI Medcl Ctr-RHU, Ann Arbor

55414

University of Minnesota, Minneapolis

55905

Mayo Clinic, Rochester

58701

Trinity Medical Group, Minot

60612

Rush University Medical Center, Chicago

63110

Washington University, St Louis

66160

University of Kansas Medical Center Research Institute, Inc., Kansas City

71103

LSU Health Sciences Center Shreveport, Shreveport

75287

Texas Health Resources, Dallas

76104

Texas Research Institute, Fort Worth

77099

Pioneer Research Solutions, Inc., Houston

78404

Adriana Pop Moody Clinic PA, Corpus Christi

85259

Mayo Clinic Scottsdale, Scottsdale

87131

University of New Mexico, Albuquerque

92354

Loma Linda University Clinical Trial Center, Loma Linda

97239

Oregon Health & Science University, Portland

02114

Massachusetts General Hospital, Boston

27599-7155

UNC Kidney Center, UNC-CH Division of Nephrology and Hypertension, Chapel Hill

02903

Rhode Island Hospital, Providence

T6G 2B7

University of Alberta Hospital, Edmonton

L8N 4A6

St. Josephs Healthcare, Hamilton

M5G 1X5

Mount Sinai Hospital, Toronto

H2X 0A9

CHUM Centre de Recherche, Québec

G8Z1Y2

Centre de Recherche Musculo-Squelettique, Trois-Rivières

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Iqvia Pty Ltd

INDUSTRY

lead

InflaRx GmbH

INDUSTRY

NCT03712345 - Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA | Biotech Hunter | Biotech Hunter